The article focuses on NOTCH1 (and also -2 and -4 as these are involved in CLL) both mutated and activated forms as applicable. I refer to these collectively as NOTCH.
The article includes among other things how NOTCH can point to limited effectiveness of ibrutinib (once you start treatment), on how a mutation may mean non-responsiveness to chemo for patients who are fit, under age 65, and umIGHV, involvement of NOTCH with Richter’s transformation, also involvement with squamous cell carcinoma, and with how it can identify an end around BCL2 (limiting the effectiveness of Venetoclax) by pointing to the presence of an alternative path to preventing apoptosis. The author even poses a good question not necessarily related to NOTCH: If you have low CD20 expression, do you really want to use an anti-CD20 antibody given its contribution to treatment toxicity. I guess if you are offered a CD20 antibody, a good question to ask is how much CD20 expression do you have.
The presentation talks about identifying resistance to Venetoclax.
The table quantifies the risk of factors associated with the development of secondary cancers in CLL.
cllsociety.org/2018/06/cll-...
Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20
Venetoclax 17p patient
Chronic lymphocytic leukemia treatment algorithm 2022
Clinical trial results & reviews of new treatments for CLL written in easy to understand terms 
